Combination Therapy Interferon Alpha + JAK1-2 Inhibitor in The Ph-Negative Chronic Myeloid Neoplasms

Trial Profile

Combination Therapy Interferon Alpha + JAK1-2 Inhibitor in The Ph-Negative Chronic Myeloid Neoplasms

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Dec 2015

At a glance

  • Drugs Ruxolitinib (Primary) ; Peginterferon alfa-2a; Peginterferon alfa-2b
  • Indications Myelofibrosis; Polycythaemia vera
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 Dec 2015 Preliminary results (n=30) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
    • 11 Dec 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top